SOURCE: CONMED Corporation
UTICA, NY--(Marketwire - May 24, 2012) - CONMED Corporation (NASDAQ: CNMD) announced today that it will host an investor and analyst meeting on Friday, June 8, 2012, at CONMED Linvatec's surgical training facilities in Largo, Florida.
This meeting will be webcast live from 8:30 am - 12:30 pm Eastern Time, and by replay. To access the webcast and presentation slides, please enter the Company's website at www.conmed.com.
Presentations on sports medicine, powered instruments and the Altrus Thermal Tissue Fusion System will be given by:
- Joseph Corasanti, President & Chief Executive Officer
- Joe Darling, President, CONMED Linvatec
- Brett Poole, Vice President, Sports Medicine
- Tom Shaffer, Vice President, Sports Tissue & Biologics
- Heather Trombley, Vice President, Hall Powered Instruments
- Dave Murray, President, Electrosurgery
Institutional investors and sell-side analysts interested in attending the investor and analyst meeting should contact Brian Ritchie of FTI Consulting at 212-850-5683 or firstname.lastname@example.org.
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,400 employees distribute its products worldwide from several manufacturing locations.
Forward Looking Information
The Investor and Analyst Meeting may involve discussion of forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements will be made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the Meeting or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation of litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.